Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes

PURPOSE: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR–TKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Liu, Yang, Zhou, Bin, Wang, Zhi, Liang, Naichao, Zhang, Yundong, Dong, Zhouhuan, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809345/
https://www.ncbi.nlm.nih.gov/pubmed/27042123
http://dx.doi.org/10.2147/OTT.S93823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809345/
https://www.ncbi.nlm.nih.gov/pubmed/27042123
http://dx.doi.org/10.2147/OTT.S93823

Ejemplares similares